BCRX Stock Analysis: Buy, Sell, or Hold?
BCRX - BioCryst Pharmaceuticals Inc
$9.91
-0.54 (-5.17%)
▼
5d:
-2.56%
30d:
+21.0%
90d:
+3.66%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 03, 2026
20d
Smart Money Accumulation
None View Scanner →
Strength: 8.0/10
Get Alerted When BCRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
8 traders called BCRX this week
67% bullish • 3 bearish
67% bullish • 3 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BCRX shows positive signals but monitor for confirmation. Market pricing in 11.6% decline. Moderate conviction.
💡 BUY OPPORTUNITY: BCRX shows positive signals but monitor for confirmation. Market pricing in 11.6% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$29.54
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$18.34
46.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BCRX is currently trading at $9.91, which is considered slightly high relative to its 30-day fair value range of $8.61 to $10.28. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.3) compared to its historical average (16.4). Remarkably, the market is currently pricing in an annual earnings decline of 11.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, BCRX is in a uptrend. Immediate support is located at $9.47, while resistance sits at $11.22. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: BCRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.90 (+109.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BCRX is in a uptrend. Immediate support is located at $9.47, while resistance sits at $11.22. Short-term momentum is weak, with the stock down 5.2% recently.
Market Sentiment: BCRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $21.90 (+109.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$8.61 -
$10.28
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.2%)
- BULLISH: Trading 109.6% below Wall St target ($21.90)
Trading Range Analysis
30-Day Trading Range
$8.61 -
$10.28
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$9.48
Resistance Level
$11.22
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.30
Wall Street Target
$21.90
(+109.6%)
Revenue Growth (YoY)
7.5%
Profit Margin
-51.7%
Valuation Discount vs History
-11.6% cheaper
PE vs Historical
11.3 vs 16.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-11.6%
(market-implied from PE analysis)
1-Year Target
$9.40
(-10%)
2-Year Target
$8.46
(-19%)
3-Year Target
$7.62
(-27%)
3-Yr Target (if PE normalizes)
(PE: 11→16)
$11.06
(+6%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 51.6%)
$67.99
(+551%)
Base:
(SPY PE: 11.3, Growth: 51.6%)
$35.27
(+238%)
Bear:
(PE: 9.6, Growth: 51.6%)
$29.98
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.3 to 16.4
Stabilization Target:
$15.17
(+45.2%)
PE Expansion Potential:
+45.2%
Share & Embed Analysis
Last updated: July 13, 2026 4:21 PM ET
Data refreshes hourly during market hours. Next update: 5:21 PM
Data refreshes hourly during market hours. Next update: 5:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Alane P Barnes
SELL
150000 shares
2026-03-16
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 51 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
Advanced BCRX Option Strategies
Professional options setups generated by AI based on today's BCRX price and gamma walls.
